A Phase 2 interventional study of Everolimus in Lymphangioleiomyomatosis, sponsored by Novartis Pharmaceuticals. Completed at 4 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-19.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Lymphangioleiomyomatosis with a site in United States — 6 open to participants now, 8 under way, 1 of them phase 3. Lymphangioleiomyomatosis · United States.
Among the 28 studies in Lymphangioleiomyomatosis with a site in United States, this one is the 11th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2010, is one of 8 in phase 2, and was the 10th registered.
49 studies on the registry are indexed under Lymphangioleiomyomatosis; 11 are open to participants now.
Browse Lymphangioleiomyomatosis studies →6 of the 28 studies in Lymphangioleiomyomatosis with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 18–64 · Women only
David M. Ritter · Sites in United States
Women only
National Tuberous Sclerosis Association · Sites in United States, Canada
University of Cincinnati · Sites in United States
Ages 18+ · Women only
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–100 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 10 Lymphangioleiomyomatosis studies recruiting now, 6 (60%) set no upper age limit and 1 (10%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 13 · Phase 3 3
First in 1995; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is close to the median of 25 across 30 interventional studies indexed under Lymphangioleiomyomatosis.
Median enrollment 24 across the 21 interventional studies, 400 across the 7 observational. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 3 studies filed under Lymphangioleiomyomatosis — fewer than ten, so there is no comparison to draw.
2 of the studies in Lymphangioleiomyomatosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06889168Columbia UniversityEvaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM) | 2026-12 |
| NCT01799538National Heart, Lung, and Blood Institute (NHLBI)Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies in Lymphangioleiomyomatosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This was an exploratory study to determine whether escalating doses of RAD001 (everolimus) were safe and effective in patients with Lymphangioleiomyomatosis
In addition to the data collected in this study, historical data from 43 patients treated with placebo from the multicenter trial of sirolimus in LAM (MILES) study (NCT00414648) were down weighted to an effective sample size of 18 for comparison of FEV1 and FVC endpoints. Reference to the publication of the MILES study has been provided under "Result Publication".
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All patients received a starting dose of everolimus 2.5mg/day for 4 weeks, followed by a dose of 5 mg/day for 4 weeks and finally a dose of 10mg/day for 18 weeks. The 26 week treatment period was followed by an optional extension period wherein patients continued therapy until the last patient had completed 26-weeks of treatment. The longest period a patient participated in the study was 62 weeks.
Drug: Everolimus
Everolimus was formulated as tablets in strengths of 2.5mg, 5mg and 10mg.
Also known as: RAD001
Change From Baseline in Vascular Endothelial Growth Factor-D (VEGF-D) Concentrations
Blood samples (1 mL) for determination of VEGF-D were collected from a forearm vein (direct venipuncture or from an indwelling cannula) and 2 aliquots of serum were collected. VEGF-D levels were determined from only 1 of the 2 serum aliquots, with the second acting as a back-up. A serum VEGF-D \>800 pg/mL level supports a diagnosis of Lymphangioleiomyomatosis (LAM)
Time frame: Baseline, 26 weeks
Mean Trough (C0,ss) and Peak (C2,ss) Drug Concentration at Steady State
Venous blood samples (2 mL) for pharmacokinetic evaluation were collected pre dose and 2 hours post dose at preselected visits.
Time frame: pre-dose and at 2 hour post dose at week 26
Change From Baseline in Forced Vital Capacity (FVC)
All spirometry evaluation followed recommendations of the Standardization of Lung Function Testing. All spirometry maneuvers were performed in sitting position whilst wearing nose clips. At least three acceptable maneuvers were performed for each time point, and results met within-test and between-test criteria for acceptability. The highest value was obtained of FVC from any of the three maneuvers that met acceptability criteria. Change from baseline in FVC was compared between everolimus and historical placebo data from multicenter trial of sirolimus in LAM. (MILES NCT00414648) due to absence of placebo group in this current study on a rare lung disease. These two studies had different study designs, so the change from baseline to 6 months (26 weeks) in MILES study was estimated from the publicly reported rate of change per month to provide a meaningful comparison. This historical control be can be viewed on the Novartis Clinical Trial Results website.
Time frame: Baseline, 26 weeks
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
All spirometry evaluation followed the recommendations of the Standardization of Lung Function Testing. All spirometry maneuvers were performed in the sitting position whilst wearing nose clips. At least three acceptable maneuvers were performed for each time point, and the results met within-test and between-test criteria for acceptability. The highest value was obtained of FEV1 from any of the three maneuvers that met acceptability criteria. Change from baseline in FEV1 was compared between everolimus and historical placebo data from the MILES study (NCT00414648) due to the absence of a placebo group in this current study on a rare lung disease. These two studies had different study designs, so the change from baseline to 6 months (26 weeks) in MILES study was estimated from the publicly reported rate of change per month in order to provide a meaningful comparison. This historical control can be viewed on the Novartis Clinical Trial Results website.
Time frame: Baseline, 26 weeks
Change From Baseline in Extended Pulmonary Function Testing
Extended pulmonary function testing such as Total Lung Capacity (TLC), Thoracic Gas Volume (TGV), Residual Volume (RV) were measured using a body plethysmograph
Time frame: Baseline, 26 weeks
Change From Baseline in Carbon Monoxide Diffusing Capacity (DLCO)
Carbon Monoxide Diffusing Capacity (DLCO) one of the extended pulmonary function testing which was also measured using a body plethysmograph.
Time frame: Baseline, 26 weeks
Change From Baseline in 6-minute Walk Test Score to Measure Exercise Capacity
A standardized 6-minute walk test (6MWT) was performed in accordance with the guidelines of the American Thoracic Society 2002. The test was done about the same time of day to avoid diurnal variation in an environment that had an adequate temperature to avoid additional burden to the patient due to heat or cold air. The distance walked in six minutes (6MWD) was recorded.
Time frame: Baseline, 26 weeks
Change From Baseline in Oxygen Saturation
Oxygen saturation means the amount of oxygen in blood stream. Oxygen saturation was measured by using a Pulse Oximeter.
Time frame: Baseline, 26 weeks
| Milestone | Everolimus |
|---|---|
| Started | 24 |
| Everolimus 2.5 mg for 4 weeks | 24 |
| Everolimus 5 mg for 4 weeks | 24 |
| Everolimus 10 mg for 18 weeks | 24 |
| Pharmacokinetics (pk) analysis set | 16 |
| Completed | 20 |
| Not completed | 4 |
| Withdrew: Adverse event | 3 |
| Withdrew: Withdrawal by subject | 1 |
| Milestone | Everolimus |
|---|---|
| Started | 20 |
| Completed | 17 |
| Not completed | 3 |
| Withdrew: Adverse event | 3 |
Blood samples (1 mL) for determination of VEGF-D were collected from a forearm vein (direct venipuncture or from an indwelling cannula) and 2 aliquots of serum were collected. VEGF-D levels were determined from only 1 of the 2 serum aliquots, with the second acting as a back-up. A serum VEGF-D \>800 pg/mL level supports a diagnosis of Lymphangioleiomyomatosis (LAM)
| pg/mL | Everolimus 2.5 mg/Day | Everolimus 5 mg/Day | Everolimus 10 mg/Day |
|---|---|---|---|
| Change From Baseline in Vascular Endothelial Growth Factor-D (VEGF-D) Concentrations | -464.3 ± 745.23 | -1113.2 ± 1468.9 | -1771.7 ± 2091.6 |
Venous blood samples (2 mL) for pharmacokinetic evaluation were collected pre dose and 2 hours post dose at preselected visits.
| ng/mL | Everolimus 2.5 mg/Day | Everolimus 5 mg/Day | Everolimus 10 mg/Day |
|---|---|---|---|
| Trough (C0, ss) | 3.1 ± 1.33 | 5.8 ± 3.02 | 11.0 ± 3.45 |
| Peak (C2, ss) | 12.1 ± 3.56 | 22.6 ± 7.22 | 45.7 ± 12.52 |
All spirometry evaluation followed recommendations of the Standardization of Lung Function Testing. All spirometry maneuvers were performed in sitting position whilst wearing nose clips. At least three acceptable maneuvers were performed for each time point, and results met within-test and between-test criteria for acceptability. The highest value was obtained of FVC from any of the three maneuvers that met acceptability criteria. Change from baseline in FVC was compared between everolimus and historical placebo data from multicenter trial of sirolimus in LAM. (MILES NCT00414648) due to absence of placebo group in this current study on a rare lung disease. These two studies had different study designs, so the change from baseline to 6 months (26 weeks) in MILES study was estimated from the publicly reported rate of change per month to provide a meaningful comparison. This historical control be can be viewed on the Novartis Clinical Trial Results website.
| mL | Everolimus |
|---|---|
| Change From Baseline in Forced Vital Capacity (FVC) | 10 (-111 to 132) |
All spirometry evaluation followed the recommendations of the Standardization of Lung Function Testing. All spirometry maneuvers were performed in the sitting position whilst wearing nose clips. At least three acceptable maneuvers were performed for each time point, and the results met within-test and between-test criteria for acceptability. The highest value was obtained of FEV1 from any of the three maneuvers that met acceptability criteria. Change from baseline in FEV1 was compared between everolimus and historical placebo data from the MILES study (NCT00414648) due to the absence of a placebo group in this current study on a rare lung disease. These two studies had different study designs, so the change from baseline to 6 months (26 weeks) in MILES study was estimated from the publicly reported rate of change per month in order to provide a meaningful comparison. This historical control can be viewed on the Novartis Clinical Trial Results website.
| mL | Everolimus |
|---|---|
| Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) | 114 (11 to 217) |
Extended pulmonary function testing such as Total Lung Capacity (TLC), Thoracic Gas Volume (TGV), Residual Volume (RV) were measured using a body plethysmograph
| Liters (L) | Everolimus |
|---|---|
| TLC | 0.199 ± 0.8645 |
| TGV | 0.267 ± 1.0368 |
| RV | 0.169 ± 0.9055 |
Carbon Monoxide Diffusing Capacity (DLCO) one of the extended pulmonary function testing which was also measured using a body plethysmograph.
| ml/min/mmHg | Everolimus |
|---|---|
| Change From Baseline in Carbon Monoxide Diffusing Capacity (DLCO) | -0.782 ± 1.5351 |
A standardized 6-minute walk test (6MWT) was performed in accordance with the guidelines of the American Thoracic Society 2002. The test was done about the same time of day to avoid diurnal variation in an environment that had an adequate temperature to avoid additional burden to the patient due to heat or cold air. The distance walked in six minutes (6MWD) was recorded.
| meters (m) | Everolimus |
|---|---|
| Change From Baseline in 6-minute Walk Test Score to Measure Exercise Capacity | 46.9 ± 115.30 |
Oxygen saturation means the amount of oxygen in blood stream. Oxygen saturation was measured by using a Pulse Oximeter.
| percentage of oxygen | Everolimus |
|---|---|
| Change From Baseline in Oxygen Saturation | 0.8 ± 2.13 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Everolimus | — | 8/24 (33.3%) | 24/24 (100%) |
| Event | Everolimus |
|---|---|
| Oedema peripheralGeneral disorders | 2/24 |
| Cardiac failureCardiac disorders | 1/24 |
| PericarditisCardiac disorders | 1/24 |
| TachycardiaCardiac disorders | 1/24 |
| Non-cardiac chest painGeneral disorders | 1/24 |
| PyrexiaGeneral disorders | 1/24 |
| BronchitisInfections and infestations | 1/24 |
| Pneumocystis jiroveci infectionInfections and infestations | 1/24 |
| PneumoniaInfections and infestations | 1/24 |
| NephrolithiasisRenal and urinary disorders | 1/24 |
| Event | Everolimus |
|---|---|
| Mouth ulcerationGastrointestinal disorders | 11/24 |
| HeadacheNervous system disorders | 9/24 |
| DiarrhoeaGastrointestinal disorders | 7/24 |
| NauseaGastrointestinal disorders | 7/24 |
| StomatitisGastrointestinal disorders | 7/24 |
| FatigueGeneral disorders | 7/24 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/24 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 7/24 |
| Oedema peripheralGeneral disorders | 6/24 |
| Aphthous stomatitisGastrointestinal disorders | 5/24 |
Everolimus arm has all patients who received study drug that is the safety analysis set.
| Age, Continuous(years) | Everolimus |
|---|---|
| Mean | 44 ± 13.4 |
| Sex: Female, Male(Participants) | Everolimus |
|---|---|
| Female | 24 |
| Male | 0 |
The record gives a start of Jan 2010, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2020, 8 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus